All News

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.

Ann Graham of MIB Agents discussed some of the challenges adolescent and young adult patients deal with after cancer diagnoses.

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

I've learned to embrace the changing nature of my body as I age, accepting the challenges and finding gratitude in each day.

From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here is the latest cancer news.

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

An expert explained recent findings from a study of pregnant women with breast cancer who underwent chemotherapy and fared better than nonpregnant patients.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.

Two nominations for the 2024 Extraordinary Healer award highlight the exceptional contributions of oncology nurses, demonstrating the power of compassionate, patient-centered care.

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.

A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

As I prepare for treatment of my chronic lymphocytic leukemia, I reflect on the challenges of aging and side effects while staying focused on living fully.

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and side effect management, among others.

Carla Chapman, a nurse at Dana-Farber Cancer Institute, is recognized for her unwavering support of patients, while Deb Christensen, an oncologist and patient advocate, dedicates her life to helping patients through volunteer work and education.

A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.

A patient advocate says that patients with breast cancer may find it challenging to feel "normal," but reconstruction advancements may help.

Receiving a diagnosis of colon cancer at age 34 was such a shocking experience, but it has helped me become more strong-willed.

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received at least two prior lines of therapy.

Former U.S. President Jimmy Carter called attention to the immunotherapy drug Keytruda, which was used to successfully treat his cancer.

Jade Distajo has made a profound impact on thousands of patients with her unwavering commitment to exceptional care, compassionate bedside manner and tireless support.

From the benefits of early adoption to the effectiveness of telehealth, here is what we reported about palliative care throughout the year.

Even after a personal connection to cancer, oncology nurse Megan has embraced the cancer space as her passion.

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.